Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Prediction of Clinical Response By Phased Variants in Circulating Tumor DNA (ctDNA) in the VALENTINE-PTCL01 Trial of Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Neha Mehta-Shah, Steven Horwitz, Pier Luigi Zinzani, Stefan K. Barta, Makoto Yamagishi, David M. Kurtz, Gensuke Takayama, Yoshiyuki Hizukuri, Weiguo Feng, Ken C. N. Chang, Takaya Moriyama, Keiko Nakajima, Ai Inoue, Emmanuel Bachy

Blood (2024) 144 (Supplement 1): 4342.

https://doi.org/10.1182/blood-2024-207594

Published: 2024

Journal Articles

Genetic alteration of class I HLA in cutaneous T-cell lymphoma

Alexa C Kwang, George E Duran, Sebastian Fernandez-Pol, Safa Najidh, Shufeng Li, Armando N Bastidas Torres, Erica B Wang, Melba Herrera, Tarek I Bandali, David M Kurtz, Youn H Kim, Michael S Khodadoust

Blood blood.2024024817.

https://doi.org/10.1182/blood.2024024817

Published: 2024

Includes: Supplemental data

Journal Articles

Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

Ruwan Gunaratne, Crystal Zhou, Jesse W. Tai, Matthew Schwede, Kailee Tanaka, Matthew Alkaitis, Raymond Yin, Brian J. Sworder, Gabriel Mannis, Ravindra Majeti, Michael S. Khodadoust, David M. Kurtz, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 4307.

https://doi.org/10.1182/blood-2023-181459

Published: 2023

Journal Articles

Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy

Jordan Goldstein, Won Seog Kim, Sang Eun Yoon, Seok Jin Kim, Mark Roschewski, Jason Westin, Ryan C Lynch, Stefan K. Alig, Sandra Close, Jacob J. Chabon, Davide Rossi, Wyndham H Wilson, Maximilian Diehn, Ash A. Alizadeh, David M. Kurtz

Blood (2023) 142 (Supplement 1): 187.

https://doi.org/10.1182/blood-2023-187759

Published: 2023

Journal Articles

End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA

Mark Roschewski, Liza Lindenberg, Esther Mena, Rahul Lakhotia, Christopher Melani, Seth M. Steinberg, Andre Schultz, Gregory Hogan, Jake J. Chabon, Sandra Close, Maximilian Diehn, Brian J. Sworder, David M. Kurtz, Ash A. Alizadeh, Wyndham H. Wilson

Blood (2023) 142 (Supplement 1): 192.

https://doi.org/10.1182/blood-2023-180007

Published: 2023

Journal Articles

Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

David M. Kurtz, Gregory Hogan, Andre Schultz, Jacob J. Chabon, Ash A. Alizadeh, Karin Havenith, Sara Samari, Tim Kopotsha, Luqiang Wang, Yajuan Qin, Ying Wang, Serafino Pantano

Blood (2023) 142 (Supplement 1): 3133.

https://doi.org/10.1182/blood-2023-179977

Published: 2023

Journal Articles

Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study

Brian J. Sworder, Sang Eun Yoon, Seok Jin Kim, Andre Schultz, Gregory Hogan, Sandra Close, Jacob J. Chabon, Maximilian Diehn, David M. Kurtz, Ash A. Alizadeh, Won Seog Kim

Blood (2023) 142 (Supplement 1): 69.

https://doi.org/10.1182/blood-2023-187650

Published: 2023

Journal Articles

CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias

Blood (2023) 142 (Supplement 1): 360.

https://doi.org/10.1182/blood-2023-182522

Published: 2023

Journal Articles

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

Lara Stepan, Sahar Ansari, Abood Okal, Justine Dell'Aringa, Ethan Thompson, Alessandro Crotta, Victor A Chow, Jeremy S. Abramson, Manali Kamdar, Jacob J. Chabon, Gregory Hogan, David M. Kurtz, Ash A. Alizadeh, Leanne Peiser

Blood (2023) 142 (Supplement 1): 225.

https://doi.org/10.1182/blood-2023-181007

Published: 2023

Journal Articles

Phased Variants Allow Robust Profiling of Circulating Tumor DNA in Untreated Follicular Lymphomas

Ákos Nagy, Bence Bátai, Gregory Hogan, Jacob J. Chabon, Mikayla Troke, Lance Riley, Andre Schultz, Sandra Close, Maximilian Diehn, Donát Alpár, Botond Timár, Ash A. Alizadeh, David M. Kurtz, Csaba Bödör

Blood (2023) 142 (Supplement 1): 1626.

https://doi.org/10.1182/blood-2023-189824

Published: 2023

Journal Articles

Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification

Jurik A Mutter, Mohammad Shahrokh Esfahani, Joseph Schroers-Martin, Stefan K. Alig, Mark P. Hamilton, Brian J. Sworder, Benoit Tessoulin, Jan Boegeholz, Timothy Flerlage, Jamie E. Flerlage, Michael S. Binkley, Takeshi Sugio, Cédric Rossi, Mari Olsen, Chih Long Liu, Steven Le Gouill, David M. Kurtz, Maximilian Diehn, Ash A. Alizadeh

Blood (2023) 142 (Supplement 1): 245.

https://doi.org/10.1182/blood-2023-186853

Published: 2023

Journal Articles

Distinct Circulating Genomic Features of Classical Hodgkin Lymphoma of Older Adults

Cédric Rossi, Jan Boegeholz, Stefan K. Alig, Andrea Garofalo, Mohammad Shahrokh Esfahani, Joseph Schroers-Martin, Mari Olsen, Xiaoman Kang, David M. Kurtz, Takeshi Sugio, Mark P. Hamilton, Marc Andre, Rene-Olivier Casasnovas, Luc Matthieu Fornecker, Maximilian Diehn, Herve Ghesquieres, Ash A. Alizadeh

Blood (2023) 142 (Supplement 1): 4369.

https://doi.org/10.1182/blood-2023-178257

Published: 2023

Journal Articles

Longitudinal Noninvasive Surveillance & Fragmentomic Characterization of Follicular Lymphoma

Joseph Schroers-Martin, Jurik A Mutter, Mohammad Shahrokh Esfahani, Florian Scherer, Joanne Soo, Stefan K. Alig, David M. Kurtz, Takeshi Sugio, Cédric Rossi, Benoit Tessoulin, Mari Olsen, Chih Long Liu, Maximilian Diehn, Ash A. Alizadeh

Blood (2023) 142 (Supplement 1): 528.

https://doi.org/10.1182/blood-2023-187116

Published: 2023

Journal Articles

Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods

Blood (2023) 142 (Supplement 1): 177.

https://doi.org/10.1182/blood-2023-186810

Published: 2023

Journal Articles

Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 1301–1303.

https://doi.org/10.1182/blood-2022-165545

Published: 2022

Journal Articles

Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling

Blood (2022) 140 (Supplement 1): 1295–1296.

https://doi.org/10.1182/blood-2022-164744

Published: 2022

Journal Articles

Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)

David M. Kurtz, Sairah Ahmed, Cheuk Ka Tong, Matthew Mei, Cliff Ding, Ian W. Flinn, Peter A. Riedell, Gregory J. Hogan, Andre Schultz, Jacob J. Chabon, Helen E. Heslop, Aung Myo, Ash A. Alizadeh, Ivan D. Horak

Blood (2022) 140 (Supplement 1): 2378–2380.

https://doi.org/10.1182/blood-2022-162150

Published: 2022

Journal Articles

Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP

David M. Kurtz, Gregory J. Hogan, Andre Schultz, Katerina Kopeckova, Christian Kuffer, Derek Blair, Steve Wagner, Sandra Close, Maximilian Diehn, Jacob J. Chabon, Ash A. Alizadeh, Jason Westin

Blood (2022) 140 (Supplement 1): 3498–3499.

https://doi.org/10.1182/blood-2022-168378

Published: 2022

Journal Articles

Accurate Detection of Clinically Actionable Copy Number Variants in Diverse Hematological Neoplasms By Routine Targeted Sequencing: A Comparative Performance Study

Alicia Palomino Mosquera, Hitomi Hosoya, Michael C. Jin, Mohammad Shahrokh Esfahani, Joseph Schroers-Martin, Brian Sworder, Chih Long Liu, Elizabeth Spiteri, Yasodha Natkunam, James L Zehnder, Henning Stehr, David M. Kurtz, Ash A. Alizadeh

Blood (2022) 140 (Supplement 1): 10712–10713.

https://doi.org/10.1182/blood-2022-167900

Published: 2022

Journal Articles

Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas

Blood (2022) 140 (Supplement 1): 1318–1319.

https://doi.org/10.1182/blood-2022-159230

Published: 2022

NARROW

Prediction of Clinical Response By Phased Variants in Circulating Tumor DNA (ctDNA) in the VALENTINE-PTCL01 Trial of Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Genetic alteration of class I HLA in cutaneous T-cell lymphoma

Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy

End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA

Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study

CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

Phased Variants Allow Robust Profiling of Circulating Tumor DNA in Untreated Follicular Lymphomas

Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification

Distinct Circulating Genomic Features of Classical Hodgkin Lymphoma of Older Adults

Longitudinal Noninvasive Surveillance & Fragmentomic Characterization of Follicular Lymphoma

Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods

Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling

Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)

Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP

Accurate Detection of Clinically Actionable Copy Number Variants in Diverse Hematological Neoplasms By Routine Targeted Sequencing: A Comparative Performance Study

Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only